Norepinephrine Infusion Dosage
Norepinephrine is the first-choice vasopressor for shock, started at 0.05-0.1 mcg/kg/min (approximately 5-10 mcg/min for a 70kg adult) and titrated to achieve a mean arterial pressure (MAP) of 65 mmHg, with typical effective doses ranging from 0.2-0.4 mcg/kg/min. 1
Initial Dosing and Titration
Start norepinephrine infusion at 0.05-0.1 mcg/kg/min and titrate upward every 5-10 minutes based on blood pressure response. The Surviving Sepsis Campaign guidelines establish norepinephrine as the first-line vasopressor with strong evidence (strong recommendation, moderate quality) 1. The target MAP of 65 mmHg represents the minimum threshold for adequate organ perfusion in most patients.
Key titration principles:
- Titrate to MAP ≥65 mmHg as the initial target
- Reassess frequently during dose escalation
- Consider higher MAP targets (75-85 mmHg) in patients with chronic hypertension, though this requires individualization
- Arterial line placement is strongly suggested for all patients requiring vasopressors 1
Dose Ranges and Clinical Significance
Recent data-driven analysis identifies three clinically meaningful norepinephrine dose ranges that correlate with mortality 2:
- Low dose: <0.2 mcg/kg/min - Associated with 14% hospital mortality
- Intermediate dose: 0.2-0.4 mcg/kg/min - Associated with 26% hospital mortality
- High dose: >0.4 mcg/kg/min - Associated with 40% hospital mortality
These cutoffs provide practical benchmarks for assessing shock severity and triggering consideration of additional vasopressor agents. Doses exceeding 0.78 mcg/kg/min represent an optimal threshold for predicting ICU mortality 3.
When to Add Second-Line Agents
Add vasopressin (0.03 units/min) when norepinephrine reaches 0.2-0.4 mcg/kg/min rather than continuing to escalate norepinephrine alone. 1, 4 This strategy is supported by the Surviving Sepsis Campaign guidelines (weak recommendation, moderate quality evidence) and helps minimize catecholamine-related complications including arrhythmias and tissue ischemia.
Alternative second-line options include:
- Epinephrine - Can be added or substituted when additional agent needed (weak recommendation, low quality evidence) 1
- Dopamine - Reserved only for highly selected patients with bradycardia and low tachyarrhythmia risk 1
Critical threshold: Doses >3.0 mcg/kg/min are associated with 100% mortality and should prompt immediate reassessment of shock etiology, fluid status, and consideration of mechanical circulatory support. 3
Special Populations
Cardiogenic Shock
In cardiogenic shock, norepinephrine can be used but requires careful consideration. Short-term dose escalation (targeting MAP 85 mmHg) is generally well-tolerated even in patients with severe myocardial dysfunction when combined with inotropic support 5. However, excessive afterload may worsen cardiac output. Consider phenylephrine or vasopressin in afterload-dependent states like severe aortic stenosis 6.
Elderly Patients
No specific dose reduction is required for elderly patients in shock states. However, elderly patients undergoing elective surgery may benefit from lower continuous infusion rates (0.06 mcg/kg/min demonstrated optimal outcomes in spinal surgery) 7. The key distinction is between acute shock resuscitation versus prophylactic use during anesthesia.
Patients with Cardiac Disease
Norepinephrine increases cardiac preload and contractility in addition to its vasopressor effects 8. In septic patients with reduced ejection fraction (≤45%), norepinephrine effectively increases cardiac output when MAP targets remain ≤75 mmHg, but this benefit disappears at higher MAP targets 8. This suggests avoiding excessive MAP targets in patients with poor ventricular function.
Common Pitfalls
Avoid these errors:
- Delaying norepinephrine initiation while pursuing aggressive fluid resuscitation - early vasopressor use during fluid resuscitation is appropriate for life-threatening hypotension 6, 1
- Escalating norepinephrine beyond 0.4 mcg/kg/min without adding vasopressin or reassessing the clinical situation
- Using dopamine as first-line therapy - it carries higher arrhythmia risk with no mortality benefit 1
- Targeting MAP >75 mmHg routinely without specific indication - higher targets don't consistently improve outcomes and may worsen cardiac function in vulnerable patients 8
Monitoring and Safety
Ischemic complications are uncommon and largely dose-independent, except for myocardial ischemia and cardiac arrest which increase at higher doses 3. This supports the strategy of adding second agents rather than pushing norepinephrine to extreme doses. Continuous arterial pressure monitoring via arterial catheter should be established as soon as practical 1.
The evidence strongly supports a catecholamine-sparing strategy: initiate norepinephrine early at appropriate doses, but add vasopressin once moderate requirements are reached (0.2-0.4 mcg/kg/min) rather than continuing to escalate norepinephrine alone 4.